Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Capital Leases (2019 - 2022)

Rhythm Pharmaceuticals (RYTM) has disclosed Capital Leases for 4 consecutive years, with $1.8 million as the latest value for Q1 2022.

  • Quarterly Capital Leases fell 25.98% to $1.8 million in Q1 2022 from the year-ago period, while the trailing twelve-month figure was $1.8 million through Mar 2022, down 25.98% year-over-year, with the annual reading at $1.9 million for FY2021, N/A changed from the prior year.
  • Capital Leases for Q1 2022 was $1.8 million at Rhythm Pharmaceuticals, down from $1.9 million in the prior quarter.
  • The five-year high for Capital Leases was $3.4 million in Q1 2019, with the low at $1.8 million in Q1 2022.
  • Average Capital Leases over 4 years is $2.6 million, with a median of $2.7 million recorded in 2020.
  • The sharpest move saw Capital Leases fell 15.1% in 2020, then dropped 25.98% in 2022.
  • Over 4 years, Capital Leases stood at $3.1 million in 2019, then fell by 12.77% to $2.7 million in 2020, then fell by 27.75% to $1.9 million in 2021, then fell by 8.43% to $1.8 million in 2022.
  • According to Business Quant data, Capital Leases over the past three periods came in at $1.8 million, $1.9 million, and $2.1 million for Q1 2022, Q4 2021, and Q3 2021 respectively.